Comparison of susceptibility of vaginal isolates of Candida to Lamisil and clotrimazole

Vulvovaginal candidiasis (VVC) is a frequent fungal disease that influences 70% of women at least once in their reproductive periods. Candida albicans is the main agent of VVC infections with 85%–90%. Approximately 5% of women suffer from a recurrent VVC. A variety of antifungal agents, including oral or topical drugs are available for treatment of VVC. The aim of this study was to compare the efficacy of treatment with Lamisil and clotrimazole in isolated Candida from VVC. One hundred isolates including 97 isolates C. albicans and 3 C. glabrata were studied. An overnight culture was grown and then a suspension with density 5×107 prepared. Lamisil and clotrimazole were used in this study. The minimum inhibitory concentration (MIC) was regarded based on the lowest concentration of drugs that inhibits the growth of the Candida isolates. Our results demonstrated that the antifungal drugs Lamisil and clotrimazole was found to be active against all Candida isolates. All 100 Candida isolates were found to be susceptible to clotrimazole with the MIC <0.125 - 1μg/ml for C. albicans isolates and 0.125μg/ml for C. glabrata. Lamisil has been also effective against all tested isolates with the MIC 0.125 - >2μg/ml for C. albicans and MIC 1 - >2μg/ml for C. glabrata. In this study clotrimazole presented amazingly brilliant antifungal activity against C. albicans and C. glabrata isolates. In our study the antifungal activities of Lamisil against both C. albicans and C. glabrata were not promising.

Candida, Lamisil, Clotrimazole, Vulvovaginal candidiasis